RATIONALE: Refractory status epilepticus (RSE) is the persistence of status epilepticus despite second-line treatment. Super-refractory SE (SRSE) is characterized by ongoing status despite 48h of anaesthetic treatment. Due to the high case fatality in RSE of 16-39%, off label treatments without strong evidence of efficacy in RSE are often administered. In single case-reports and small case series totalling 28 patients, acute implantation of VNS in RSE was associated with 76% and 26% success rate in generalized and focal RSE respectively. We performed an updated systematic review of the literature on efficacy of VNS in RSE/SRSE by including all reported patients.
INTRODUCTION
Status epilepticus (SE) is a condition resulting from either the failure of seizure termination mechanisms or from initiation of mechanisms which enable abnormally prolonged seizures and can have long-term consequences including neuronal death, neuronal injury, and alteration of neuronal networks [1] . The annual incidence of SE in adults is 36.9 / 100.000 in M A N U S C R I P T
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a Western European cohort [2] . The incidence is highest in children, elderly and in resource poor countries with up to 82 episodes / 100.000 / year [3] [4] [5] . Refractory SE (RSE) is defined as persistence of SE despite treatment with benzodiazepines, used as first-line treatment, and one antiepileptic drug administered as second-line treatment; super-refractory SE (SRSE) is characterized by ongoing SE despite 48h of anaesthetic treatment [6, 7] . SE represents a significant burden on health care providers: one study estimated the annual costs of SE in Germany at 200 million € [8] . The majority of costs and resource consumption associated with SE can be attributed to RSE and SRSE which require significantly longer hospitalization and more intensified treatment and monitoring [9] . Furthermore RSE and SRSE are associated with high case fatality: one-year mortality rates for RSE and SRSE were found to be 22% and 36% respectively in a recent retrospective analysis of national ICU admissions in Finland [10] .
Due to the high case fatality in RSE and SRSE, off-label treatments, many approved for treating refractory epilepsy but without evidence of efficacy in RSE or SRSE are often administered [11, 12] . Anaesthetics pose the backbone of RSE/SRSE therapy. It is however unclear which is the optimal choice of anaesthetic as controlled or comparative studies are lacking [7] . An expert review on outcomes RSE/SRSE treatments stresses the lack of outcome data in RSE/SRSE and neccessity of urgent remediation but also takes into account that suffciently-powered randomized or controlled studies are not feasible in relation to the many therapies used in combination in this uncommon and heterogenous condition [13] .
Vagus Nerve Stimulation (VNS) was approved for adjunctive treatment of drug resistant epilepsy (DRE) in Europe in 1994 and in the USA in 1997 and involves intermittent electrical stimulation of the left cervical vagus nerve by means of an implanted helical electrode connected to a pulse generator (VNS Physicians Manual). Evidence for seizure termination M A N U S C R I P T
by VNS is limited to experimental studies [14] and case reports [15, 16] . Although it has been documented that VNS reduces the occurrence and re-occurrence of SE [17, 18] it remains a matter of debate whether acute implantation of VNS in a patient with SE may be beneficial in terminating the episode of SE. Single case-reports and small case series of acute VNS implantation in RSE were included in a systematic review published in 2015; VNS was associated with RSE cessation in 76% of general and 26% of focal RSE [19] . We performed an updated systematic review of the literature on efficacy of VNS in RSE/SRSE by including all reported patients.
METHODS
The results of the present systematic review was reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and adheres to a structured review protocol [20] .
Search Strategy and Article Selection
Two authors (F.B. and M.D.A.) performed a search of EMBASE, CENTRAL, Opengre.eu, ClinicalTrials.gov, and PubMed databases using the following search strategy: ("VNS" OR "vagal nerve stimulation" OR "vagus nerve stimulation") AND ("status epilepticus" OR "NORSE" OR "FIRES" OR "Febrile infection-related epilepsy syndrome"). The same search strategy was used to search for conference abstracts from AES and ILAE meetings of the past 5 years. The authors then independently excluded non-relevant articles based on review of the full-text articles before comparing selected publications reporting on outcomes of patients with any type of status epilepticus that were implanted with a vagus nerve stimulator published in English language were included. Upon uncertainty of inclusion of a publication an additional author was consulted.
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Data extraction
From each article the primary endpoint of cessation or not of the RSE/SRSE episode in which VNS was implanted was extracted. A positive outcome was defined as either cessation of the acute RSE/SRSE episode in which a VNS was implanted and no report of later death or a significant (>50%) reduction in the most debilitating seizure type or seizure-freedom/no reoccurrence of status epilepticus. The following data were collected if reported: focal or generalized RSE/SRSE convulsive or non-convulsive SE, age, sex, epilepsy type (in case of a patient with epilepsy), epilepsy etiology, SE etiology, treatments prior to and after VNS, duration of SE prior to VNS and time to cessation, VNS parameters and long-term outcome.
Classification of articles
Grading of level of evidence was carried out using the American Academy of Neurology's (AAN) classification scheme [21] . The AAN defines a Class I and a Class II study as a randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment with a Class II study lacking one criterion a-e of Class I [21] or being a prospective matched cohort study that meets b-e Class I. Class III trials are all other controlled trials (e.g. natural history controls or patients serving as their own controls) in a representative population, where outcome is independently assessed or derived by objective outcome measurements. Class IV studies are those not meeting Class I, II, or III criteria including consensus or expert opinion. 
Statistical analysis
RESULTS
Study selection and Level of Evidence
The described search strategy yielded 395 publications (Figure 1 ) of which 33 were duplicates. Of the remaining 363 publications 335 were excluded for not reporting on outcomes of patients with status epilepticus treated with VNS and therefore being irrelevant to this analysis. The remaining 28 publications were screened leading to exclusion of two relevant abstracts that reported on the same patient [22, 23] as one full-text article included in this analysis [24] . Finally, 26 articles describing 45 patients with status epilepticus treated with VNS were included in this analysis . 38 patients underwent acute implantation of VNS in an episode of RSE/SRSE. Five cases describe VNS implantation in refractory epilepsia partialis continua, one in refractory electrical status epilepticus in sleep and one in acute encephalitis with refractory repetitive focal seizures. According to the AAN level of evidence classification scheme all studies included in this analysis were classed as level IV evidence.
Primary endpoints
Acute VNS implantation was associated with cessation of RSE/SRSE in 74% (28/38) of acute cases (Table 1a) . Cessation did not occur in 18% (7/38) of cases. In 3 cases, only long-term outcomes (outcomes after the SE episode) were reported hence whether acute VNS implantation was associated with the cessation of the RSE/SRSE was unclear. Positive (Table 1b) .
Etiologies and treatments
Etiologies for RSE/SRSE were reported for 45% (17/38) of the acute cases and ranged from AED withdrawal in people with epilepsy (n=5) to different causes of encephalitis (n=6). A fever was reported in 7 cases and 13 patients suffered from an epileptic encephalopathy. 
Duration of RSE/SRSE pre-and post VNS implantation
The duration of the RSE/SRSE episode pre-and post VNS implantation is reported in 34% (13/38) and 50% (19/38) of cases respectively ( Table 2 ). The median duration of the RSE/SRSE episode prior to VNS implantation was 18 days (range: 3 -1680 days) and median duration post VNS implantation was 8 days (range: 3-84 days).
VNS parameters
Information on programming of VNS devices was reported in 50% (19/38) of the acute cases.
Median output current was 1.5 mA (range 1-3 mA), median frequency was 30 Hz (range 20-30 Hz), median pulse-width 500 µsec (range 250 -500µsec) and median duty cycle was 16 % (range 10-58%) indicating rapid titration of stimulation.
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Adverse Events
Not all included studies reported adverse events which prevents a systematic analysis thereof. One patient experienced recurrent bradycardia and hypotonia (under comedication with thiopental) on post-operative day 4, leading to asystole and resuscitation without complications. The patient continued on VNS with no further episodes. One patient with Febrile Infection-Related Epilepsy Syndrome (FIRES) experienced intermittent bradycardia after dose escalation up to 1.75 mA over 36h. One patient with EPC experienced seizure aggravation when stimulation was increased from 0.25 mA to 0.5 mA which was reversed at reduction to 0.25 mA. Four deaths were reported (11%); all of them due to the underlying disease and unlikely related to VNS implantation. One of the four deaths occurred in a 25 year-old man 13 days after acute VNS implantation for NORSE, which initially interrupted the SRSE episode for 72 hours. There was however a reoccurrence of SRSE which was fatal. The second death occurred a month after VNS implantation in an infant in whom the episode of SRSE could not be terminated. The second death occurred in a child with FIRES 15 days after VNS implantation which failed to interrupt the episode of SRSE leading to severe bilateral cortical edema and multi-organ failure. The third death occurred after a GTCS in an 82 year-old man one year after VNS implantation.
DISCUSSION
With all its limitations this systematic literature review found acute VNS implantation to be associated with cessation of RSE/SRSE in 74% (28/38) of cases with a median duration of the RSE/SRSE episode post VNS implantation of 8 days (range 3-84 days). Cessation was found to not occur in 18% (7/38) of cases and four deaths were reported (11%); all of them unlikely related to VNS implantation. Positive outcomes (either cessation of the acute RSE/SRSE M A N U S C R I P T
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episode in which a VNS was implanted and no report of later death or a significant (>50%) reduction in the most debilitating seizure type or seizure-freedom/no reoccurrence of status epilepticus) occurred in 79% (31/38) of cases.
With high case fatality [2, 10] RSE and SRSE represent devastating conditions, however beyond anaesthetics, the basis of RSE/SRSE therapy, it is unclear which therapeutic approach is most optimal as controlled or comparative studies are lacking [7] .
Next to internalization of synaptic GABA receptors and increase of surface NMDA-receptors, induction of epigenetic and genetic changes leading to altered expression of proteins with excitatory and inhibitory properties (e.g. substance P) initiating hours and days after SE onset are considered to contribute to refractoriness towards agents targeting classic antiepileptic targets [49, 50] . On this basis, new treatment approaches are being investigated with non-drug approaches potentially offering particular benefit in drug-refractory SE. Many of these treatments and their current level of evidence have been summarized in a recent systematic review by Arya et al [51] . A Class I trial found therapeutic hyperthermia not to be more effective than standard care in treating RSE/SRSE and raised safety concerns [52] .
Despite the inherent challenge of a pre-surgical evaluation in an ongoing episode of SE a few small series describe treatment of RSE/SRSE by resective surgery: SRSE ceased in 10 out of 10 patients with 7/10 patients being seizure-free at 7 months [53] . A recent review of case reports describing use of electro-convulsive therapy to treat RSE/SRSE found electrographic resolution in 6 out of 8 cases, but recovery to baseline in only 2 patients [54] . Isolated reports describe also successful use of anterior thalamic deep-brain stimulation to treat RSE/SRSE [55] . Similar to VNS, the ketogenic diet (KD) has been administered to patients with RSE and SRSE in clinical practice however with fewer cases reported than for VNS. A recent case-series of 14 paediatric patients with RSE treated with KD found electrographic M A N U S C R I P T
seizure resolution along with ≥50% suppression in 10/14 patients within 7 days of starting the KD. Eleven out of 14 patients could be weaned off continuous infusions within 2 weeks of starting KD [56] . Despite what one may classify as positive outcomes in these small series, use of KD in RSE and SRSE is cautious: the authors note that KD was under-utilized, as the 14 patients derived from a cohort of 239 RSE patients and there was a median delay of 14 days after SE onset, before KD was initiated.
Long-term studies in heterogeneous DRE populations show that VNS elicits a > 50% reduction in seizure frequency in approximately 60% of patients [57, 58] . Anti-ictal and antiepileptogenic mechanisms of action of VNS have been investigated extensively, however it remains unclear which of the many effects of VNS are responsible for clinical seizure reduction and cessation in epilepsy patients. It is well documented that VNS increases firing rates and metabolic activity in the nucleus tractus solitarius (NTS) of the brainstem and in the structures directly connected to it [59] . Of these connections the dorsal raphe nucleus (DRN) and locus coeruleus (LC) of the brainstem are of special interest as they represent the main serotonin and norepinephrine producing sites of the brain and increased levels of these mono-amines and their metabolites have been found both in patients treated with VNS and in preclinical studies with VNS [60] [61] [62] [63] [64] . Stimulation of norepinephrine release from the brainstem and its binding in the limbic system has been proposed as a key anti-epileptic mechanism of VNS as blockade of hippocampal α2-receptors inhibits the anti-epileptic effect of VNS in Wistar rats [61] . Of particular interest in status epilepticus may be results from one SPECT study suggesting that response to VNS may be associated with modulation of cortical GABA A receptor expression. Seizure reduction correlated with GABA A receptor density in patients after 1 year of VNS but not in matched controls [65] .
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Furthermore, quantitative EEG studies using different measures of synchronization suggest that VNS may acutely desynchronize the inter-ictal EEG thereby impeding the development of hypersynchronous rhythms [66] . VNS also acutely desynchronizes ictal-rhythms thereby containing seizure propagation of focal-onset seizures [67] . Electrographic seizure interruption by VNS has been demonstrated in rats and dogs [68] [69] [70] but only anecdotally in humans [15, 16] . Taken together, multiple mechanisms by which VNS may contribute to cessation of RSE/SRSE are conceivable; however have yet to be proven in well controlled trials.
Limitations
The results of this systematic review must be interpreted with great caution as the analysis is limited by the inherent property of systematic reviews of ignoring potentially important differences across studies as well as by the low sample sizes and low evidence class of studies included. Additionally there was high heterogeneity in reporting of outcomes with some studies failing to report basic patient demographics such as sex or age of the patients, which of course impacts data quality. Complete documentation of all treatments before and after VNS was only available for some of the cases included in this analysis and the majority of cases failed to report electrographic outcomes.
Studying the efficacy of [adjunctive] treatments for SE is a general challenge, as it can be unclear which of the multiple treatments (or a combination thereof) has been effective or if the SE episode would have ceased without the intervention.
There is also great need for standardization of efficacy criteria in studies of RSE/SRSE and efforts have been made to evaluate the influence of different efficacy criteria on the results of observational studies on treatment of SE [71] . Redecker et al found that "last drug M A N U S C R I P T
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introduced into the antiepileptic therapy or increased in dose within 24h before termination of the SE without changes in the co-medication" was the most appropriate measure for the evaluation of efficacy of an AED in the treatment of SE and more reasonable than the "last antiepileptic drug (AED) administered before SE termination" [72] . Median latency from VNS implant to RSE/SRSE cessation was 8 days in this analysis and similar for KD, which is far beyond the frame of the former mentioned efficacy measure.
Duration of SE is known to represent a key predictor of outcome with mortality increasing 5-fold in patients with SE episodes lasting longer than 60 minutes compared to those in whom SE could be successfully treated within 30 minutes [73] and increased length of hospitalization representing a predictor of functional disability [74] . Randomized-controlled trials aimed at minimizing these biases can however be extremely difficult and even impossible to execute in RSE/SRSE, due patient recruitment challenges in a rare and emergency condition with heterogenous etiologies as well as for ethical reasons.
Finally, this analysis contains a high fraction of case-reports which brings a high risk of reporting bias, potentially resulting in overly optimistic outcomes. Negative case-reports are M A N U S C R I P T
less likely to be submitted for publication as there is lower interest from journals to publish them and low expectation from authors of acceptance.
The cases summarized in this systematic review are the only data currently available offering insight into acute VNS implantation in RSE/SRSE and therefore carry relevance in documenting this practiced treatment approach. Since the previous 2015 systematic review by Zeiler et al more detailed case reports and case series have been published leading to this analysis being able to include 36% more cases. Furthermore, the previous analysis does not report on long-term outcomes, VNS settings, treatments applied prior to VNS implantation or duration of the SE episode post VNS implantation which represent important considerations. These aspects have been captured in this analysis as they are necessary to shape a prospective observation of acute implantation of VNS in RSE/SRSE, which the authors understand to be of great importance in overcoming the inherent bias of the current analysis and therefore are in the process of initiating.
CONCLUSION
Outcomes of our analysis are in line with those from the previous analysis suggesting that VNS has potential in interrupting RSE and SRSE in many patients with an overall response rate of 74%. Data quality however is low (level IV) and the risk for reporting bias is high.
Further prospective studies are warranted to investigate the role of acute VNS in RSE and SRSE and should elucidate optimal stimulation paradigms, timing of the acute implantation and potential synergies with pharmacological agents. 
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